Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer's Disease and Cerebral Amyloid Angiopathy

- Single Doses of ALN-APP Demonstrated Dose-Dependent, Rapid and Sustained Reduction of sAPPα and sAPPβ in Cerebrospinal Fluid, with Up to 90% at Highest Dose to Date - - Encouraging... | April 26, 2023

Related Keywords

United Kingdom ,Canada ,Netherlands ,Cambridge ,Cambridgeshire ,United States ,Pushkal Garg ,Alexandra Bowie ,Christine Regan Lindenboom ,Yvonne Greenstreet ,Georged Yancopoulos ,Bryan Crowe ,Regeneron Genetics Center ,Linkedin ,Alnylam Pharmaceuticals ,Novartis ,Twitter ,Exchange Commission ,Alnylam Pharmaceuticals Inc ,Regeneron Pharmaceuticals Inc ,Nasdaq ,Securities Exchange ,Instagram ,Sustained Reduction ,Cerebrospinal Fluid ,Highest Dose ,Clinical Safety ,Tolerability Profile Observed ,Single Dosing ,Provide First Demonstration ,Gene Silencing ,Human Brain Using Alnylam ,Chief Medical Officer ,Chief Executive Officer ,Chief Scientific Officer ,Nobel Prize Winning ,Forward Looking Statements ,Regeneron Pharmaceuticals ,Product Candidates ,Securities Act ,Securities Exchange Act ,Quarterly Reports ,Media Contact ,Investor Contact ,Nc Stock Exchange ,News ,Information ,Press Release ,Single ,Doses ,F ,Remonstrated ,Rapid ,End ,Sustained ,Reduction ,N ,Cerebrospinal ,Ith ,P ,O ,It ,Highest ,Nose ,Ate Regn Us75886f1075 ,